Cannabidiphorol

Cannabidiphorol, the heptyl-homologue of cannabidiol was identified as a natural phytocannabinoid and named cannabidiphorol in 2019. It had previously been reported as a synthetic compound, but was not identified as a natural product prior to 2019. Recently, CBDP has since gained popularity due to it being synthesized and available on a commercial level.

Pharmacology

CBDP shows weak antagonism at both cannabinoid receptors, similar to cannabidiol. CBD, however, exhibits stronger antagonism at CB2, reaching a 33% maximum response of SR144528 versus CBDP's 23%.
Both cannabinoids act as weak agonists at the serotonin 5-HT1A receptor, contributing to potential anxiolytic effects.
Unlike CBD, CBDP shows no sign of dopamine D2 receptor agonism.
Unexpectedly, CBDP acts as a positive allosteric modulator at the MOR, enhancing met-enkephalin signaling by 37%, potentially affecting pain perception.